A two-cohort study published in General Psychiatry reports that serum levels of the body's own glucagon-like peptide-1 were significantly elevated in patients with Alzheimer's disease compared with controls, and rose progressively with disease stage. The authors frame the hormone as a candidate biomarker rather than a treatment target.

GLP-1 is best known as the incretin hormone that drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) mimic, but it is also produced in the brain. This paper is not about those drugs: it measures the hormone people make themselves, and asks what its level says about the disease. The authors note that GLP-1 receptor agonists have shown neuroprotective effects in preclinical Alzheimer's models while results in human trials have been inconsistent and limited.

Two cohorts, 250 participants

The researchers analyzed two independent Chinese cohorts, Renji with 123 participants and SheMountain with 127, spanning cognitively unimpaired people, mild cognitive impairment and Alzheimer's dementia. Alongside serum GLP-1 they measured GFAP, amyloid-beta 40 and 42, and pTau217, plus APOE genotyping, neuropsychological testing, MRI and amyloid PET, with postmortem tissue from the prefrontal cortex and hippocampus.

The gradient across the continuum

Concentrations increased step by step from cognitively normal individuals through mild cognitive impairment to dementia, in both brain tissue and serum. Serum GLP-1 correlated negatively with MoCA cognitive scores and positively with GFAP, pTau217 and brain amyloid burden.

A compensatory signal that does not hold

Serial mediation analysis placed GLP-1 and GFAP statistically along the association between amyloid burden and tau pathology, which the authors read as a compensatory response that is ultimately insufficient. Machine learning models combining GLP-1 with the other biomarkers reached an area under the curve of 0.896.

Limitations

This is cross-sectional association work in two cohorts of modest size, and mediation analysis describes statistical positioning, not a demonstrated causal chain. The authors are explicit that the physiological role of endogenous GLP-1 during disease progression remains poorly understood, with conflicting findings across previous patient cohorts.

Bottom line

An AUC of 0.896 from a blood panel is a genuinely interesting number in a field where diagnostic confirmation still leans on PET. What the paper does not establish is whether measuring endogenous GLP-1 adds anything beyond the pTau217 and GFAP already in the model.